Alteogen Inc. says it has signed an option and licensing agreement with Novartis AG to develop and commercialize subcutaneous (SC) formulations for multiple products using Alteogen’s ALT-B4 technology. The companies frame the deal as enabling biologics that are given intravenously (IV) to be converted into SC formulations. Alteogen’s Hybrozyme platform technology underpins ALT-B4, which involves a recombinant human hyaluronidase.
Korea Times reports the agreement is worth up to 4.4 trillion won (about $3.2 billion), contingent on development and commercialization milestones. It also says Novartis receives exclusive rights through multiple options and that Alteogen is to earn royalties on net sales after commercialization. PR Newswire similarly describes Novartis obtaining development and commercialization rights for several Hybrozyme-enabled subcutaneous products, and notes the arrangement is Alteogen’s fourth ALT-B4 licensing agreement signed this year.
Across outlets, the key differences are mainly in presentation: PR Newswire emphasizes the expansion of the Hybrozyme platform and the number of licensing agreements, while Korea Times provides the reported deal value and additional detail on exclusivity, options, royalties, and the ALT-B4 mechanism.
